GlobeNewswire
Dublin, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension (2020-2025) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Pulmonary Arterial Hypertension Market is estimated to be USD 7.4 Bn in 2020 and is expected to reach USD 9.9 Bn by 2025, growing at a CAGR of 6%.Some of the factors that impact the growth of the global pulmonary arterial hypertension market are the change in the lifestyles, rising geriatric population, and the increasing prevalence of pulmonary arterial hypertension (PAH). Several Government and private sector initiatives such as the rare disease act and the orphan drug act that create awareness and offer incentives such as tax waivers, credits, assistance & support are expected to contribute to the growth rate of the global pulmonary arterial hypertension market.However, discontinuing of drug production by major players during clinical trials and stringent regulations by Government, lack of awareness about the presence of pulmonary arterial hypertension among patients, and high diagnosis and treatment cost are expected to hinder the market growth. Technology advancements such as biomarker and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.Market Dynamics Drivers Growing Burden of Pulmonary Arterial HypertensionGovernment and Private Support for the Development of Orphan DrugsGrowing Geriatric Population Restraints Patent Expiration of Key MoleculesSide Effects Associated with the DrugsLack of Awareness among People in Developing Countries Challenges High Costs of Diagnosis and TreatmentLack of AwarenessExpiry of Patents Opportunities Advance Oral Drugs for Pulmonary Arterial HypertensionTechnology Advancements such as Biomaker and New Gene Therapy for the Treatment Segments Covered Based on Drug Class, the pulmonary arterial hypertension (PAH) market has been segmented into Soluble Guanylate Cyclase (SGC) stimulators, prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), and Endothelin Receptor Antagonists (ERA). ERA And Prostacyclin And Prostacyclin Analogs for treating PAH have the largest market share owing to the significant increase in the sales of this drug for the treatment of pulmonary arterial hypertension.Based on Distribution Mode, Online Pharmacies is expected to grow at the highest CAGR during the forecast period. An increase in preferences for e-commerce platforms and also due to the benefits provided by the online pharmacies like discounts & home delivery are fueling the growth of the market.Based on Route of Administration, the Oral Route is expected to have the largest share of the market. This is because of the wide range of benefits associated with oral drugs. The oral route is one of the simplest, most convenient, and safest routes.North America is anticipated to have a large market share due to the developed healthcare infrastructure in the developed countries like U.S. that has access to advanced therapeutics for treating PAH. Increasing awareness about Pulmonary Arterial Hypertension, a growing diagnosis rate, and supportive government initiatives resulted in an increased demand for PAH diagnosis and treatment. Europe is followed by North America. The rising geriatric population, changes in lifestyle, and exposure to pollution is anticipated to contribute toward the increasing prevalence of PAH in Europe.Some of the companies covered in this report are United Therapeutics Corporation, GlaxoSmithKline plc, Novartis International AG, AstraZeneca, Bayer Healthcare AG, Pfizer Inc., Gilead Sciences, Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company Limited. and others.Competitive Quadrant The report includes Infogence Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market.Tortoise: Companies that are slow in growth, having a long legacy, and stable or negative in performance. Why buy this report? The report offers a comprehensive evaluation of the Global Pulmonary Arterial Hypertension Market.The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.The report also contains a competitive analysis using the Competitive Quadrant, a Proprietary competitive positioning tool. Report Highlights: A complete analysis of the market including parent industryImportant market dynamics and trendsMarket segmentationHistorical, current, and projected size of the market based on value and volumeMarket shares and strategies of key playersRecommendations to companies for strengthening their foothold in the market Key Topics Covered: 1. Report Description1.1 Study Objectives 1.2 Market Definition1.3 Currency1.4 Years Considered1.5 Language1.6 Key Shareholders2. Research Methodology2.1 Research Process2.2 Data Collection and Validation2.2.1 Secondary Research2.2.2 Primary Research2.3 Market Size Estimation2.4 Assumptions of the Study2.5 Limitations of the Study3. Executive Summary4. Market Overview4.1 Introduction 4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Trends5. Market Analysis5.1 Porter's Five Forces Analysis5.2 Impact of COVID-195.3 Ansoff Matrix Analysis6. Global Pulmonary Arterial Hypertension Market, By Drug Class6.1 Introduction6.2 Prostacyclin and Prostacyclin Analogs6.3 Soluble Guanylate Cyclase (Sgc) Stimulators6.4 Endothelin Receptor Antagonists (ERAs)6.5 Phosphodiesterase 5 (Pde-5)6.6 Calcium Channel Blockers6.7 Others7. Global Pulmonary Arterial Hypertension Market, By Route of Administration7.1 Introduction7.2 Oral 7.3 Injectable8. Global Pulmonary Arterial Hypertension Market, By Distribution Mode8.1 Introduction8.2 Hospital Pharmacy8.3 Online Pharmacy8.4 Retail Pharmacy 9. Global Pulmonary Arterial Hypertension Market, By Geography9.1 Introduction9.2 North America9.2.1 US9.2.2 Canada9.2.3 Mexico9.3 South America9.3.1 Brazil9.3.2 Argentina9.4 Europe9.4.1 UK9.4.2 France9.4.3 Germany9.4.4 Italy9.4.5 Spain9.4.6 Rest of Europe9.5 Asia-Pacific9.5.1 China9.5.2 Japan9.5.3 India9.5.4 Indonesia9.5.5 Malaysia9.5.6 South Korea9.5.7 Australia9.5.8 Russia9.5.9 Rest of APAC9.6 Rest of the World9.6.1 Qatar9.6.2 Saudi Arabia9.6.3 South Africa9.6.4 United Arab Emirates9.6.5 Latin America10. Competitive Landscape10.1 Infogence Competitive Quadrant10.2 Market Share Analysis10.3 Competitive Scenario10.3.1 Mergers & Acquisitions10.3.2 Agreements, Collaborations, & Partnerships10.3.3 New Product Launches & Enhancements10.3.4 Investments & Fundings11. Company Profiles11.1 Gilead Sciences, Inc.11.2 United Therapeutics Corporation11.3 Novartis International AG11.4 GlaxoSmithKline Plc. (GSK)11.5 Pfizer, Inc.11.6 Dong-A ST Co., Ltd.11.7 Merck Sharp & Dohme Corp.11.8 Bayer HealthCare AG11.9 Arena Pharmaceuticals11.10 Actelion Pharmaceuticals Ltd11.11 Daiichi Sankyo Company, Limited11.12 Gilead Sciences11.13 Johnson & Johnson11.14 AstraZeneca 11.15 Bristol-Myers Squibb Company12. Appendix12.1 Questionnaire For more information about this report visit https://www.researchandmarkets.com/r/mqgah7 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo Movies
